MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceBusiness Wire • 06/21/24
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)Business Wire • 06/20/24
Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 06/14/24
MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating FactorsSeeking Alpha • 06/05/24
Are Medical Stocks Lagging Mind Medicine MindMed (MNMD) This Year?Zacks Investment Research • 05/29/24
The Time Traveler's Portfolio: 3 Stocks to Buy Now for Massive Returns by 2034InvestorPlace • 05/23/24
New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the USBusiness Wire • 05/09/24
MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New YorkBusiness Wire • 05/04/24
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business UpdateBusiness Wire • 05/02/24
This Small-Cap Stock Is Up 140% This Year and Here's Why It Can Go Even HigherThe Motley Fool • 04/25/24
Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment DataSeeking Alpha • 04/04/24